Evidence map›Paper›PMID 41154340›Full record

ArticleCancers2025

Prognostic Impact of Infectious Agents After Definitive Treatment in Non-Small Cell Lung Cancer.

Özlem Koca, Umur Kağan Kahya, Meltem Beydilli Şahiner, Rahmi Atıl Aksoy, Timur Koca, Aylin Fidan Korcum

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Özlem KocaDepartment of Medical Microbiology, Antalya Training and Research Hospital, University of Health Sciences, Antalya 07070, Turkey.ORCID 0000-0002-7167-7794
Umur Kağan KahyaDepartment of Radiation Oncology, Akdeniz University School of Medicine, Antalya 07070, Turkey.ORCID 0009-0009-6890-2303
Meltem Beydilli ŞahinerDepartment of Radiation Oncology, Akdeniz University School of Medicine, Antalya 07070, Turkey.ORCID 0009-0003-3775-3794
Rahmi Atıl AksoyDepartment of Radiation Oncology, İzmir City Hospital, İzmir 35530, Turkey.ORCID 0000-0002-5399-5430
Timur KocaDepartment of Radiation Oncology, Akdeniz University School of Medicine, Antalya 07070, Turkey.ORCID 0000-0002-7400-1837
Aylin Fidan KorcumDepartment of Radiation Oncology, Akdeniz University School of Medicine, Antalya 07070, Turkey.ORCID 0000-0003-0318-6122

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfections are common complications in patients with non-small cell lung cancer (NSCLC) and may adversely influence clinical outcomes. Their prognostic impact after definitive treatment is not well established. This study aimed to investigate the incidence, microbiological profile, and prognostic significance of infections occurring within one year after definitive treatment in patients with NSCLC.

methodsWe retrospectively analyzed patients with NSCLC who completed definitive treatment between 1 January 2016, and 31 December 2023. Microbiological culture results obtained within one-year post-treatment and inflammatory markers measured one month after treatment were evaluated. Pathogens were classified as healthcare-associated infection (HAI) or non-HAI agents. Overall survival (OS) was estimated using the Kaplan-Meier method, and prognostic factors were assessed using Cox regression analysis.

resultsAmong 214 eligible patients, 45 had positive microbiological cultures. Gram-negative bacteria predominated (n = 24), with

conclusionInfections within the first year after definitive treatment, particularly those caused by HAI-related Gram-negative pathogens, are associated with reduced OS in NSCLC. Early microbiological diagnosis, targeted antimicrobial therapy, and strict infection prevention strategies may help improve outcomes in this high-risk population.

Indexed as

chemoradiotherapyhealthcare-associated infectionsinfectionsnon-small cell lung canceroverall survival

Identifiers

PMID41154340
PMCPMC12564440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.